Herpes simplex DNA vaccine - Vical

Drug Profile

Herpes simplex DNA vaccine - Vical

Alternative Names: HSV-2 DNA vaccine - Vical; HSV-2 glycoprotein D vaccine - Vical; VCL HB01; VCL-HB01 HSV-2 Therapeutic Vaccine; VCL-HM01

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vical
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Herpes simplex virus infections

Most Recent Events

  • 19 Apr 2017 Vical completes enrolment in a phase II clinical trial for Herpes simplex virus infections in USA (NCT02837575) (IM)
  • 27 Sep 2016 Phase-II clinical trials in Herpes simplex virus infections (In adults) in USA (IM) (NCT02837575)
  • 20 Jun 2016 Efficacy and adverse events data from a phase I/II trial in Herpes simplex virus infections released by Vical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top